Bionano reports Q3 2026 revenue up 12% on reimbursement and publication progress
The company cited OGM reimbursement and state approval steps and three new studies while reiterating 2026 revenue guidance of $31 to $33 million.
Bionano Genomics reported financial results for the third quarter ended September 30, 2026 on November 10, 2026. Chairman and interim CEO Al Luderer said the quarter's results reflect momentum building across the business and the broader genomics community, further accelerating adoption of optical genome mapping in clinical and commercial settings.1 He said coverage and regulatory developments in the quarter contributed to a clearer reimbursement path for OGM testing, which the company expects to support wider clinical uptake over time.1 He also noted that major academic cancer centers are adding OGM to their clinical labs, widening the pool of regular users driving product use.1
On the operating side, Bionano Laboratories disclosed several OGM-related updates tied to reimbursement coverage and state-level approvals for OGM tests sold by outside providers.1 The company also pointed to new data support, saying it had three independent peer-reviewed papers published on OGM's clinical value in myelodysplastic syndromes, acute myeloid leukemia, and therapy-related myeloid neoplasms.1
Financially, total revenue reached $8.3 million, up 12% from $7.4 million in the third quarter of 2025.1 Consumables revenue rose 24% to $4.7 million.1 Flowcell sales climbed 18% to 9,870 units from 8,390 a year earlier.1 Gross margin was 48%, versus 46% in the prior-year quarter.1 Operating expenses fell 12% to $10.5 million, while adjusted operating expense dropped 9% to $8.8 million.1
The company reiterated its full-year 2026 revenue guidance of $31 to $33 million.1
Fact check notes
- Checker's noteThe entry states cash and cash equivalents were 'down from $2,990,000 at December 31, 2025' but the balance sheet shows cash increased from $2,990,000 to $4,355,000 over that period — the direction is reversed.
- Sentence removed
As of the quarter's end, the balance sheet showed cash and cash equivalents of $4,355,000, down from $2,990,000 at December 31, 2025, with total current assets of $25,517,000 and total stockholders' equity of $28,210,000.
contradicted: Cash actually increased from $2,990,000 to $4,355,000; the entry incorrectly states it decreased.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.